Quizartinib

Acute Myeloid Leukemia

Daiichi SankyoSmall moleculePhase 3Active

B

63/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 65/ 100
Competitive Position: 59/ 100

Competitive context

684 Active assets in the Acute Myeloid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Gemtuzumab M.D. Anderson Cancer Center	Phase 4	A
Cytosin-Arabinosid Institute of Hematology & Blood Diseases Hospital, China	Phase 3	BBB
AMSACRINE University Hospital, Toulouse	Phase 4	BBB
Posaconazole AstraZeneca	Phase 4	BBB
(+)-VINCRISTINE Janssen Research & Development, LLC	Phase 3	BBB

View all 50 →

Same molecule, other indications

Quizartinib is also rated in:

myelodysplastic syndromeDormant

BB

Indicative ·

67 / 100

acute myeloid leukemia, FLT3 internal tandem duplicationDormant

BB

Indicative ·

64 / 100

childhood acute myeloid leukemiaDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.